Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
    • Governance
    • Financials
    • Stock Information
    • Investor Resources
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
    • Governance
    • Financials
    • Stock Information
    • Investor Resources
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
    • Governance
    • Financials
    • Stock Information
    • Investor Resources
  • Contact

Archives: Resources

PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressureenabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma

…

Enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus systemic delivery

…

Pancreatic Venous Anatomy for Trans-Portal Treatment of Pancreatic Cancers using Pressure Enabled Drug Delivery (PEDD)

…

The effects of a pressure-enabled drug delivery microcatheter on radiotracer distribution compared to a standard microcatheter in radioembolization, an interim analysis

…

Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors with authors.

…

Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.

…

Pressure-enabled intravascular delivery of SD-101 into the liver with systemic or subcutaneous checkpoint inhibitor for control of liver metastases in a murine model

…

Pressure-Enabled Drug Delivery (PEDDTM) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model

…

Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD) Versus a Standard Endhole Catheter

…

Improved delivery of a TLR-9 agonist to liver tissue by intravascular pressure enabled drug delivery (PEDD) compared with direct needle injection

…
← older
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL